The U.S. FDA has given its final approval to the first generic Narcan (naloxone hydrochloride) nasal spray to stop or reverse the effects of an opioid overdose. It marks the latest step in the agency's efforts to combat the opioid crisis. The agency tentatively approved this product from Teva Pharmaceuticals USA Inc. June 8, 2018. Parent Teva Pharmaceutical Industries Ltd. is located in Petach Tikva, Israel.